ALLMedicine™ Acromegaly Center
Research & Reviews 1,243 results
https://clinicaltrials.gov/ct2/show/NCT03882034
May 27th, 2022 - Growth hormone excess is a rare and potentially lethal condition associated with hypersecretion of growth hormone (GH), usually by a pituitary tumor or hyperplasia. When it occurs prior to the complete fusion of growth plates, it leads to patholog...
https://clinicaltrials.gov/ct2/show/NCT00001987
May 27th, 2022 - Study Description: Insulin is the key hormone responsible for regulating the level of glucose in plasma. In several disease states (e.g., obesity, type 2 diabetes, and acromegaly), the target cells are resistant to insulin action. Insulin resistan...
https://doi.org/10.20945/2359-3997000000481
Archives of Endocrinology and Metabolism; Kizilgul M, Duger H et. al.
May 26th, 2022 - It is reported that adding cabergoline to somatostatin analog (SSA) normalizes IGF-1 levels approximately in one-third of patients with acromegaly. We investigated the effect of combination therapy and potential predictors of response in patients ...
https://doi.org/10.1007/s12020-022-03082-z 10.1210/jc.2014-2700. 10.1210/clinem/dgz096. 10.1016/S0140-6736(04)16044-3. 10.1210/clinem/dgab560. 10.1007/s40618-016-0565-y. 10.1210/jcem.86.7.7634. 10.1046/j.1365-2265.1998.00536.x. 10.1530/ERC-16-0553. 10.1210/jc.2017-02457. 10.1023/a:1015713732717. 10.1210/jc.2015-2372. 10.1210/jcem.83.8.5007. 10.1210/jc.2009-2670. 10.1055/a-0859-1883. 10.1055/s-0043-102569. 10.1089/thy.2015.0020. 10.1371/journal.pone.0127276. 10.4158/EP-2020-0398. 10.1016/j.ando.2019.03.001. 10.1053/j.gastro.2019.12.002. 10.1016/j.gie.2016.03.791. 10.1530/EJE-18-0255. 10.1007/s11102-020-01090-8. 10.3389/fendo.2019.00390. 10.1210/er.2018-00166. 10.1530/EJE-10-0896.
Endocrine Durmuş ET, Atmaca A et. al.
May 25th, 2022 - To investigate the prevalence of cancer in patients with acromegaly and the variables associated with malignant and premalignant lesions detected by cancer screening. The data of 214 patients diagnosed with acromegaly in our institution were evalu...
https://doi.org/10.1007/s00264-022-05447-5 10.1210/jc.2014-2700 10.1023/a:1009965803750 10.1007/s11102-016-0754-x 10.3389/fendo.2019.00268 10.1210/jcem.83.10.5222 10.1210/jc.2003-032041 10.1210/jc.2003-031199 10.1530/EJE-16-0117 10.1210/jc.2004-2297 10.1016/j.ghir.2010.02.003 10.1530/EJE-08-0845 10.1002/art.1780330332 10.1007/BF03347225 10.1136/ard.30.3.243 10.1155/2012/839282 10.23938/ASSN.0928 10.1210/jc.2008-2393 10.1007/s00264-011-1235-5 10.1136/bmjopen-2019-033045 10.1016/j.ghir.2021.101389 10.1210/clinem/dgaa747 10.1302/0301-620X.75B2.8444942 10.2106/00004623-199702000-00003 10.1302/0301-620X.69B1.3818732 10.1007/s40618-020-01268-8 10.1136/ard.2010.131698 10.1016/j.ghir.2013.05.003 10.1016/j.joca.2014.08.015 10.1097/00003086-198303000-00017 10.13107/jocr.2250-0685.768
International Orthopaedics; Akkaya M, Pignataro A et. al.
May 22nd, 2022 - Acromegaly is a rare and chronic hormonal disorder. Persons with acromegaly frequently live well into adulthood. Patients with active acromegaly have multiple joint-related issues; however, acromegalic arthropathy (AA), which is secondary osteoart...
Guidelines 5 results
https://doi.org/10.1016/j.numecd.2016.02.001
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD; Baroni MG, Giorgino F et. al.
Feb 26th, 2016 - Hyperglycemia is a common feature associated with states of increased growth hormone secretion and glucocorticoid levels. The purpose of these guidelines is to assist clinicians and other health care providers to take evidence-based therapeutic de...
https://doi.org/10.1038/nrendo.2014.21
Nature Reviews. Endocrinology; Giustina A, Chanson P et. al.
Feb 26th, 2014 - In March 2013, the Acromegaly Consensus Group met to revise and update guidelines for the medical treatment of acromegaly. The meeting comprised experts skilled in the medical management of acromegaly. The group considered treatment goals covering...
https://www.ncbi.nlm.nih.gov/pubmed/21846616
Endocrine Practice : Official Journal of the American Col... Katznelson L, Atkinson JL et. al.
Aug 24th, 2011 - American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update.|2011|Katznelson L,Atkinson JL,Cook DM,Ezzat SZ,Hamrahian AH,|diagnosis,therapy,standards,trends,...
https://www.ncbi.nlm.nih.gov/pubmed/19923883
Journal of Endocrinological Investigation; Cozzi R, Baldelli R et. al.
Jan 23rd, 2010 - AME Position Statement on clinical management of acromegaly.|2010|Cozzi R,Baldelli R,Colao A,Lasio G,Zini M,|diagnosis,economics,epidemiology,therapy,
https://doi.org/10.1210/jc.2008-2421
The Journal of Clinical Endocrinology and Metabolism; Melmed S, Colao A et. al.
Feb 12th, 2009 - The Acromegaly Consensus Group reconvened in November 2007 to update guidelines for acromegaly management. The meeting participants comprised 68 pituitary specialists, including neurosurgeons and endocrinologists with extensive experience treating...
Drugs 26 results see all →
Clinicaltrials.gov 70 results
https://clinicaltrials.gov/ct2/show/NCT03882034
May 27th, 2022 - Growth hormone excess is a rare and potentially lethal condition associated with hypersecretion of growth hormone (GH), usually by a pituitary tumor or hyperplasia. When it occurs prior to the complete fusion of growth plates, it leads to patholog...
https://clinicaltrials.gov/ct2/show/NCT00001987
May 27th, 2022 - Study Description: Insulin is the key hormone responsible for regulating the level of glucose in plasma. In several disease states (e.g., obesity, type 2 diabetes, and acromegaly), the target cells are resistant to insulin action. Insulin resistan...
https://clinicaltrials.gov/ct2/show/NCT04837040
Apr 29th, 2022 - A randomized, placebo-controlled study designed to evaluate the safety and efficacy of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with acromegaly previously treated with so...
https://clinicaltrials.gov/ct2/show/NCT03158090
Mar 16th, 2022 - The study was designed to answer some of the most important questions about the treatment modalities of acromegaly, the relevance of these treatment modalities to patients' clinical outcomes and the economic impact of treatment programs on patient...
https://clinicaltrials.gov/ct2/show/NCT04522180
Jan 10th, 2022 - This is a multi-center, open-label, randomized, Phase 2 study of IONIS-GHR-LRx in up to 40 participants with acromegaly. Participants will be randomized to 1 of 3 treatment groups to receive a single dose of IONIS GHR-LRx monthly for 73 weeks. At ...
News 97 results
https://www.medscape.com/viewarticle/969871
Mar 8th, 2022 - Dr Douglas S. Paauw A 64-year-old woman is evaluated for fever, diarrhea, and abdominal pain. She was diagnosed with Clostridioides difficile 2 months ago and completed a 10-day course of vancomycin. Her stool toxin test is positive for Clostridio...
https://www.mdedge.com/internalmedicine/article/252401/infectious-diseases/practice-guidelines-highlights-past-year
Douglas S. Paauw, MD
Mar 3rd, 2022 - A 64-year-old woman is evaluated for fever, diarrhea, and abdominal pain. She was diagnosed with Clostridioides difficile 2 months ago and completed a 10-day course of vancomycin.
https://www.medscape.com/viewarticle/966233
Jan 10th, 2022 - NEW YORK (Reuters Health) - Many patients with acromegaly may do as well on oral octreotide treatment as they do on injectable somatostatin receptor ligands (iSRLs), an industry-sponsored phase-3 trial suggests. Oral octreotide is the first oral m...
https://www.medscape.com/viewarticle/963018
Nov 15th, 2021 - Takeaway Circulating insulin-like growth factor-I (IGF-I) was associated with several common conditions (other than cancer), including a positive association with carpal tunnel syndrome and inverse associations with varicose veins and iron deficie...
https://www.medpagetoday.com/endocrinology/generalendocrinology/91617
Mar 14th, 2021 - The FDA accepted a new drug application and set a review date of October 31 for Marius Pharmaceuticals' Kyzatrex, an oral testosterone undecanoate softgel, for primary and secondary male hypogonadism. The Endocrine Society released a new scientifi...